Harvard Bioscience (NASDAQ: HBIO) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
This table compares Harvard Bioscience and Invivo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Harvard Bioscience and Invivo Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Harvard Bioscience presently has a consensus price target of $9.00, suggesting a potential upside of 97.80%. Invivo Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 1,150.00%. Given Invivo Therapeutics’ higher probable upside, analysts clearly believe Invivo Therapeutics is more favorable than Harvard Bioscience.
Institutional & Insider Ownership
61.6% of Harvard Bioscience shares are held by institutional investors. Comparatively, 12.0% of Invivo Therapeutics shares are held by institutional investors. 9.8% of Harvard Bioscience shares are held by insiders. Comparatively, 3.9% of Invivo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Harvard Bioscience has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.
Earnings & Valuation
This table compares Harvard Bioscience and Invivo Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Harvard Bioscience||$104.52 million||1.52||-$4.30 million||($0.09)||-50.56|
|Invivo Therapeutics||N/A||N/A||-$23.43 million||($0.85)||-0.56|
Harvard Bioscience has higher revenue and earnings than Invivo Therapeutics. Harvard Bioscience is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Harvard Bioscience beats Invivo Therapeutics on 9 of the 13 factors compared between the two stocks.
About Harvard Bioscience
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
About Invivo Therapeutics
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.